NCT05439993View on ClinicalTrials.gov

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Gastric CancerGastroesophageal-junction Cancer
Interventions
DRUG

Tepotinib plus paclitaxel

Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks

Trial Locations (1)

Unknown

RECRUITING

Hallym University Medical Center, Gyeonggi-do

All Listed Sponsors
lead

Hallym University Medical Center

OTHER